Healthier Future Initiatives for the Eastern Mediterranean Region

By Melike Belenli Gümüş

October 30, 2024

A recent article from the World Health Organization’s Eastern Mediterranean Regional Office (EMRO) highlights three flagship initiatives aimed at achieving a healthier future for the region. These initiatives are essential for expanding equitable access to medical products, improving health workforce resilience, and addressing substance use issues.

Expanding Equitable Access to Medical Products

This initiative aims to improve access to quality medical products, which is essential for closing the healthcare access gap in the Eastern Mediterranean Region. The primary strategies involve developing a new regional pooled procurement mechanism to enhance accessibility and boost countries’ bargaining power with manufacturers. Furthermore, the initiative provides ongoing technical support at the national level to strengthen domestic capacities for the production, distribution, and regulation of medical products.

Investing in a Resilient and Sustainable Health Workforce

The health workforce is the backbone of every effective health system. However, the initiative addresses a severe shortage of health professionals in the region, which is projected to face a shortfall of 2.1 million doctors, nurses, and midwives. Therefore, the initiative focuses on several key aspects to strengthen the health workforce. Investing in health workers is essential for increasing life expectancy, creating jobs, and supporting economic and social development. The initiative also promotes equitable occupational opportunities and aims to protect health professionals from harm. Ultimately, the goal is to build a resilient, fit-for-purpose, and sustainable health workforce across the region, achieving health security by 2030.

Accelerating Public Health Action on Substance Use

Substance use is a significant and growing public health challenge in the region, and this initiative seeks to tackle it by reducing the economic, social, and health burdens associated with substance use disorders. It addresses the alarming 137% increase in drug use disorders over the past 30 years. The initiative aims to ensure that more people receive the necessary treatment, as currently only 1 in 13 people in the region receive treatment compared to 1 in 5 globally. To achieve these goals, the initiative plans to implement strategic region-wide actions and collaborate with other United Nations agencies and partners, as well as provide country-specific interventions and support.

Overall Vision and Objectives

The WHO Regional Director for the Eastern Mediterranean, Dr. Hanan Balkhy, emphasises that these flagship initiatives are part of an ambitious vision to ensure the best attainable level of health for everyone. Expanding equitable access to medical products is a core aspect of this vision. The initiatives align with the WHO’s Fourteenth General Programme of Work and aim to accelerate progress toward achieving the health-related Sustainable Development Goals (SDGs) by 2030. By focusing on these initiatives, the region can make significant strides toward a healthier future for all.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.